BioXcel Therapeutics Announces FDA Clearance of IND Application for BXCL501 for the Treatment of Opioid Withdrawal Symptoms Feb 5, 2020
BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 Study of BXCL501 for Acute Treatment of Agitation Associated with Dementia Jan 7, 2020
BioXcel Therapeutics Announces Initiation of Pivotal Phase 3 Studies of BXCL501 for Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder Dec 30, 2019
BioXcel Therapeutics to Expand Study of BXCL701 into Multiple Advanced Solid Tumor Types Dec 11, 2019
BioXcel Therapeutics Prepares to Initiate Pivotal Phase 3 Studies with BXCL501 Following Positive End-of-Phase 2 Meeting with FDA Dec 3, 2019
BioXcel Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update Nov 14, 2019
BioXcel Therapeutics to Host Third Quarter 2019 Operating and Financial Results Conference Call and Webcast Nov 7, 2019
BioXcel Therapeutics to Present at the 26th Annual Prostate Cancer Foundation Scientific Retreat Oct 24, 2019
